New antiarrhythmic treatment of atrial fibrillation

References

• Naccarelli GV, Wolbrette DL, Khan M et al. Old and new antiarrhythmic drugs for converting and maintaining sinus rhythm in atrial fibrillation: comparative efficacy and results of trials. Am. J. Cardiol.91, 15D–26D (2003).
   PubMed Web of Science ®Google Scholar
• Fuster V, Ryden LE, Cannom DS et al. ACC/AHA/ESC 2006 guidelines for the management of atrial fibrillation – executive summary. J. Am. Coll. Cardiol.48, 854–906 (2006).
   PubMed Web of Science ®Google Scholar
• Ross HM, Kowey PR, Naccarelli GV. New antiarrhythmic pharmacologic therapies and regulatory issues in antiarrhythmic drug development. In: New Arrhythmia Technologies Wang P (Ed.). Blackwell Publishing, Oxford, UK 3–13 (2005).
   Google Scholar
• Naccarelli GV, Lukas M. Carvedilol’s antiarrhythmic properties: therapeutic implications in patients with left ventricular dysfunction. Clin. Cardiol.28, 165–173 (2005).
   PubMed Web of Science ®Google Scholar
• Katritsis DG, Panagiotakos DB, Karvouni E et al. Comparison of effectiveness of carvedilol versus bisoprolol for maintenance of sinus rhythm after cardioversion of persistent atrial fibrillation. Am. J. Cardiol.92, 1116–1119 (2003).
   PubMed Web of Science ®Google Scholar
• Merritt JC, Niebaur M, Tarakji K, Hammer D, Mills RM. Comparison of effectiveness of carvedilol versus metoprolol or atenolol for atrial fibrillation appearing after coronary artery bypass grafting or cardiac valve operation. Am. J. Cardiol.92, 735–736 (2003).
   PubMed Web of Science ®Google Scholar
• Kanoupakis EM, Manios EG, Mavkaris HE et al. Comparative effects of carvedilol and amiodarone on conversion and recurrence rates of persistent atrial fibrillation. Am. J. Cardiol.94, 659–662 (2004).
   PubMed Web of Science ®Google Scholar
• Khand AU, Rankin AC, Martin W et al. Carvedilol alone or in combination with digoxin for the management of atrial fibrillation in patients with heart failure? J. Am. Coll. Cardiol.42, 1944–1951 (2003).
   PubMed Web of Science ®Google Scholar
• Camm AJ, Savelieva I. Advances in antiarrhythmic drug treatment of atrial fibrillation: where do we stand now? Heart Rhythm1, 244–246 (2004).
   PubMed Web of Science ®Google Scholar
• Singh S. Trials of new antiarrhythmic drugs for maintenance of sinus rhythm in patients with atrial fibrillation. J. Interv. Card. Electrophys.10, S71–S76 (2004).
   PubMed Web of Science ®Google Scholar
• Choudhury A, Lip GY. Antiarrhythmic drugs in atrial fibrillation: an overview of new agents, their mechanisms of action and potential clinical utility. Expert Opin. Investig. Drugs13, 841–855 (2004).
   PubMed Web of Science ®Google Scholar
• Matyus P, Varga I, Rettegi T et al. Novel antiarrhythmic compounds with combined class IB and class III mode of action. Curr. Med. Chem.11, 61–69 (2004).
   PubMed Web of Science ®Google Scholar
• Castro A. Bianconi L, Santini M. New antiarrhythmic drugs for the treatment of atrial fibrillation. PACE25, 249–259 (2002).
   Google Scholar
• Weiss JN, Garfinkel A, Chen PS. Novel approaches to identifying antiarrhythmic drugs. Trends Cardiovasc. Med.13, 326–330 (2003).
   PubMed Web of Science ®Google Scholar
• Tamargo J, Caballero R, Delpon E. New mechanistic targets for the treatment of atrial fibrillation. In: Atrial Fibrillation: New Therapeutic Concepts. Papp JP, Straub M, Ziegler D (Eds). IOS Press, Amsterdam, The Netherlands 133–155 (2003).
   Google Scholar
• Padanilam B, Prystowsky E. New antiarrhythmics agents for the prevention and treatment of atrial fibrillation. J. Cardiovasc. Electrophysiol.17(3), S62–S66 (2006).
   Web of Science ®Google Scholar
• Musco S, Seltzer J, Kowey PR. Future directions in antiarrhythmic drug therapy for atrial fibrillation. Future Cardiol.2(5), 545–553 (2006).
   PubMedGoogle Scholar
• Freestone B, Lip GY. Tedisamil: a novel antiarrhythmic. Expert Opin. Investig. Drugs13, 151–160 (2004).
   PubMed Web of Science ®Google Scholar
• Hohnloser SH, Dorian P, Straub M, Beckmann K, Kowey P. Safety and efficacy of intravenously administered tedisamil for rapid conversion of recent-onset atrial fibrillation or atrial flutter. J. Am. Coll. Cardiol.44, 99–104 (2004).
   PubMed Web of Science ®Google Scholar
• Fedida D, Orth P, Chen J et al. The mechanism of atrial antiarrhythmic action of RSD1235. J. Cardiovasc. Electrophysiol.17, S71–S78 (2006).
   PubMedGoogle Scholar
• Dorian P, Mangat I, Korley V. The investigational antiarrhythmic agent RSD1235 is atrially selective in humans. Circulation112, II-94 (2005).
   Google Scholar
• Roy D, Rowe BH, Stiell IG et al; for the CRAFT Investigators. A randomized, controlled trial of RSD 1235, a novel anti-arrhythmic agent, in the treatment of recent onset atrial fibrillation. J. Am. Coll. Cardiol.44, 2355–2361 (2004).
   PubMed Web of Science ®Google Scholar
• Roy D, Pratt C, Wyse DG et al. RSD1235 for conversion of atrial fibrillation. The Phase III Atrial Arrhythmia Conversion Trial. Presented at Heart Rhythm Society 2005 26th Annual Scientific Sessions New Orleans, LA, USA 4–7 May 2005.
   Google Scholar
• Pratt C, Roy D, Juul-Moller S et al. Efficacy and tolerance of RSD1235 in the treatment of atrial fibrillation or atrial flutter: results of a Phase III, randomized, placebo-controlled, multicenter trial. J. Am. Coll. Cardiol.47, 10A (2006) (Abstract).
   Google Scholar
• Pratt CM, Navratil J, Nagy A et al. Oral vernakalant (RSD1235-SR) prevents recurrence of atrial fibrillation following cardioversion. Heart Rhythm4, S176 (2007) (Abstract).
   Google Scholar
• Goldstein RN, Khrestian C, Carlsson L, Waldo AL. AZD7009: a new antiarrhythmic drug with predomiant effects on the atria effectively terminates and prevents reinduction of atrial fibrillation and flutter in the sterile pericarditis model. J. Cardiovasc. Electrophysiol.15, 1444–1450 (2004).
   PubMed Web of Science ®Google Scholar
• Geller CJ, Crijns HJ, Egstrup K et al. Pharmacological conversion with intravenous AZD7009 is as effective as DC cardioversion in patients with persistent atrial fibrillation lasting <30 days. Heart Rhythm4, S178 (2007) (Abstract).
   Google Scholar
• Blaauw Y, Gogelein H, Tieleman RG, van Hunnik A, Schotten U, Allessie MA. “Early” class III drugs for the treatment of atrial fibrillation. Efficacy and atrial selectivity of AVE0118 in remodeled atria of the goat. Circulation.110, 1717–1724 (2004).
   PubMed Web of Science ®Google Scholar
• de Haan S, Greiser M, Harks E et al. AVE0118, Blocker of the transient outward current (Ito) and ultrarapid delayed rectifier current (IKur), fully restores atrial contractility after cardioversion of atrial fibrillation in the goat. Circulation.114, 1234–1242 (2006).
   PubMed Web of Science ®Google Scholar
• Hynes J, Wolbrette DL, Luck JC, Khan M, Samii S, Naccarelli GV. A review of the pharmacokinetics, electrophysiology and clinical efficacy of dronedarone. Future Cardiol.1, 135–144 (2005).
   PubMedGoogle Scholar
• Tafreshi MJ, Rowles J. A review of the investigational antiarrhythmic agent dronedarone. J. Cardiovasc. Pharmacol. Ther.12, 15–26 (2007).
   PubMed Web of Science ®Google Scholar
• Dale KM, White CM. Dronedarone: an amiodarone analog for the treatment of atrial fibrillation and atrial flutter. Ann. Pharm.41, 599–605 (2007).
   PubMed Web of Science ®Google Scholar
• Sun W, Sarma JSM, Singh BN. Electrophysiological effects of dronedarone (SR33589), a noniodinated benzofuran derivative, in the rabbit heart. Comparison with amiodarone. Circulation100, 2276–2281 (1999).
   PubMed Web of Science ®Google Scholar
• Touboul P, Brugada J, Capucci A et al. Dronedarone for prevention of atrial fibrillation: a dose-ranging study. Eur. Heart J.24, 1481–1487 (2003).
   PubMed Web of Science ®Google Scholar
• Singh BN, Hohnloser SH, Connolly SJ et al. The EURIDIS and ADONIS Trials: dronedarone for maintaining sinus rhythm in patients with atrial fibrillation/flutter. Circulation110(Suppl.), III-741 (2003) (Abstract).
   Google Scholar
• Sun W, Sarma JSM, Singh BN. Chronic and acute effects of dronedarone on the action potential of rabbit atrial muscle preparations: comparison with amiodarone. J. Cardiovasc. Pharmacol.39, 677–684 (2002).
   PubMed Web of Science ®Google Scholar
• Gauthier P, Guillemare E, Marion A et al. Electrophysiologic characterization of dronedarone in guinea pig ventricular cells. J. Cardiovasc. Pharmacol.41, 191–202 (2003).
   PubMed Web of Science ®Google Scholar
• Varro A, Takacs J, Nemeth M et al. Electrophysiological effects of dronedarone (SR 33589), a noniodinated amiodarone derivative in the canine heart: comparison with amiodarone. Br. J. Pharmacol.133, 625–634 (2001).
   PubMed Web of Science ®Google Scholar
• Tschuppert Y, Buclin T, Rothuizen LE et al. Effect of dronedarone on renal function in healthy subjects. Clin. Pharmacol. Ther.2, P10–P19 (2005).
   Google Scholar
• Davy JM. Dronedarone demonstrates additional rate control on top of standard pharmacotherpaies in the treatment of atrial fibrillation. Circulation112, II-577 (2005).
   Google Scholar
• Hohnloser SH. Dronedarone significantly decreases the combined endpoint of hospitalization and death in atrial fibrillation. Circulation112, II-327 (2005) (Abstract).
   Google Scholar
• Kowey PR, Aliot EM, Capucci A et al. Placebo-controlled double-blind dose-ranging study of the efficacy and safety of SSR149744C in patients with recent atrial fibrillation/flutter. Heart Rhythm4, S72 (2007) (Abstract).
   Google Scholar
• Ellenbogen K, O’Neill G, Prystowsky E et al. Trial to evaluate the management of paroxysmal supraventricular tachycardia during an electrophysiology study with tecadenoson. Circulation111, 3202–3208 (2006).
   Web of Science ®Google Scholar
• Gollob MH, Jones DL, Krahn AD et al. Somatic mutations in the connexin 40 gene (GJA5) in atrial fibrillation. N. Engl. J. Med.354, 2677–2688 (2006).
   PubMed Web of Science ®Google Scholar
• Haugan K, Olsen K, Hartvig L et al. The antiarrhythmic peptide analog ZP123 prevents atrial conduction slowing during metabolic stress. J. Cardiovasc. Electrophysiol.16, 537–545 (2005).
   PubMed Web of Science ®Google Scholar
• Guerra J, Everett IVT, Lee K, Wilson E, Olgin J. Effects of the gap junction modifier rotigaptide (ZP123) on atrial conduction and vulnerability to atrial fibrillation. Circulation114, 110–118 (2006).
   PubMed Web of Science ®Google Scholar
• Shiroshita-Takeshita A, Sakabe M, Haughan K, Hennan JK, Nattel S. Model-dependent effects of the gap junction conduction-enhancing antiarrhythmic peptide rotigaptide (ZP123) on experimental atrial fibrillation in dogs. Circulation115, 310–318 (2007).
   PubMed Web of Science ®Google Scholar
• Ehrlich J, Hohnloser S, Nattel S. Role of angiotensin system and effects of its inhibition in atrial fibrillation: clinical and experimental evidence. Eur. Heart J.27, S12–S18 (2006).
   PubMed Web of Science ®Google Scholar
• Pederson OD, Bagger H, Kober L, Torp-Pedersen C. Trandolopril reduces the incidence of atrial fibrillation after acute myocardial infarction in patients with left ventricular dysfunction. Circulation100, 376–380 (1999).
   PubMed Web of Science ®Google Scholar
• Anand K, Mooss AN, Hee TT, Mohiuddin SM. Meta-analysis: inhibition of renin–angiotensin system prevents new-onset atrial fibrillation. Am. Heart J.151, 217–222 (2006).
   Google Scholar
• Ueng K-C, Tsung-Po T, Wen-Chung Y et al. Use of enalapril to facilitate sinus rhythm maintenance after external cardioversion of long-standing persistent atrial fibrillation. Eur. Heart J.24, 2090–2098 (2003).
   PubMed Web of Science ®Google Scholar
• Murray KT, Rottman JN, Arbogast PG et al, and the AFFIRM Investigators. Inhibition of angiotensin II signaling and recurrence of atrial fibrillation in AFFIRM. Heart Rhythm1, 669–675 (2004).
   PubMed Web of Science ®Google Scholar
• Madrid AH, Bueno MG, Rebollo JMG et al. Use of irbesartan to maintain sinus rhythm in patients with long-lasting persistent atrial fibrillation. A prospective and randomized study. Circulation106, 331–336 (2002).
   PubMed Web of Science ®Google Scholar
• Wachtell K, Lehto M, Gerdts E et al. Angiotensin II receptor blockade reduces new-onset atrial fibrillation and subsequent stroke compared to atenolol. J. Am. Coll. Cardiol.45, 712–719 (2005).
   PubMed Web of Science ®Google Scholar
• Kumagai K, Nakashima H, Urata H, Gondo N, Arakawa K, Saku K. Effects of angiotensin II type 1 receptor antagonist on electrical and structural remodeling. J. Am. Coll. Cardiol.41, 2197–2204 (2003).
   PubMed Web of Science ®Google Scholar
• The ACTIVE Steering Committee. Rationale and design of ACTIVE: the atrial fibrillation clopidogrel with irbesartan for prevention of vascular events. Am. Heart J.151, 1187–1193 (2006).
   PubMed Web of Science ®Google Scholar
• Young-Xu Y, Jabbour S, Goldberg R et al. Usefulness of statin drugs in protecting against atrial fibrillation in patients with coronary artery disease. Am. J. Cardiol.92, 1379–1383 (2003).
   PubMed Web of Science ®Google Scholar
• Ozaydin M, Varol E, Aslan S et al. Effect of atorvastatin on the recurrence of atrial fibrillation after electrical cardioversion. Am. J. Cardiol.97, 1490–1493 (2006).
   PubMed Web of Science ®Google Scholar
• Siu CW, Lau CP, Tse HF. Prevention of atrial fibrillation recurrence by statin therapy in patients with lone atrial fibrillation after successful cardioversion. Am. J. Cardiol.92, 1343–1345 (2003).
   PubMed Web of Science ®Google Scholar
• Patti G, Chello M, Candura D et al. Randomized trial of atorvastatin for reduction of postoperative atrial fibrillation in patients undergoing cardiac surgery. Results of the ARMDYA-3 (Atorvastatin for Reduction of Myocardial Dysrhythmia After cardiac surgery) study. Circulation114, 1455–1461 (2006).
   PubMed Web of Science ®Google Scholar
• Marin F, Pascual DA, Roldan V et al. Statins and postoperative risk of atrial fibrillation following coronary artery bypass grafting. Am. J. Cardiol.97, 55–60 (2006).
   PubMed Web of Science ®Google Scholar
• Xiao Y-F Gomez AM, Morgan JP, Lederer WJ, Leaf A. Suppression of voltage-gated L-type Ca2+ currents by polyunsaturated fatty acids in adult and neonatal rat ventricular myocytes. Proc. Natl Acad. Sci. USA94, 4182–4187 (1997).
   PubMed Web of Science ®Google Scholar
• Dhein S, Michaelis B, Mohr FW. Antiarrhythmic and electrophysiological effects of long-chain omega-3 polyunsaturated fatty acids. Arch. Pharmacol.371, 202–211 (2005).
   Google Scholar
• Ninio DM, Murphy KJ, Howe PR, Saint DA. Dietary fish oil protects against stretch-induced vulnerability to atrial fibrillation in a rabbit model. J. Cardiovasc. Electrophysiol.16, 1189–1194 (2005).
   PubMed Web of Science ®Google Scholar
• Reiffel JA, McDonald A. Antiarrhythmic effects of omega-3 fatty acids. Am. J. Cardiol.98, 50i–60i (2006).
   PubMed Web of Science ®Google Scholar
• Mozaffarian D, Psaty B, Rimm E et al. Fish intake and risk of incident atrial fibrillation. Circulation110(4), 367–373 (2004).
   Google Scholar
• Mozaffarian D, Prineas RJ, Stein PK, Siscovick DS. Dietary fish and n-3 fatty acid intake and cardiac electrophysiology parameters in humans. J. Am. Coll. Cardiol.48, 478–484 (2006).
   PubMed Web of Science ®Google Scholar
• Calo L, Bianconi L, Colivicchi F et al. N-3 fatty acids for the prevention of atrial fibrillation after coronary artery bypass surgery. J. Am. Coll. Cardiol.45, 1723–1728 (2005).
   PubMed Web of Science ®Google Scholar
• Biscione F, Totteri A, De Vita A. Effect of omega-3 fatty acids on the prevention of atrial arrhythmias. Ital. Heart J.6, 53–59 (2005).
   Google Scholar
• Brouwer IA, Heeringa J, Geleinse JM et al. Intake of very long-chain n-3 fatty acids from fish and incidence of atrial fibrillation. The Rotterdam Study. Am. Heart J.151, 857–862 (2006).
   PubMed Web of Science ®Google Scholar